A national database analysis suggests that antiplatelet drugs may play a protective role in cases of AAA before surgery is warranted. The authors outline next research steps.
The DACAB trial made headlines at AHA 2017, but it’s not likely to impact practice very much. Cardiac surgeon Faisal Bakaeen, MD, explains why.
Yet another cardiometabolic effect has been linked to the gut microbial metabolite TMAO: increased thrombotic risk stemming from platelet hyperreactivity. The lead Cleveland Clinic researcher discusses the implications.